WCLC 2024: AEGEAN Trial Update on Perioperative Durvalumab in Resectable NSCLC

By: Julia Cipriano, MS
Posted: Monday, September 9, 2024

Based on the first planned interim analyses of the phase III AEGEAN trial, perioperative use of the monoclonal antibody durvalumab plus neoadjuvant chemotherapy was safe and active in patients with resectable non–small cell lung cancer (NSCLC). The second planned interim analysis focusing on survival data, which was presented during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract OA13.03) by John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, further supported this approach as a new treatment option.

A total of 799 patients with treatment-naive stage II to IIIB disease and an Eastern Cooperative Oncology Group performance status score of 0 or 1 were administered neoadjuvant platinum-based chemotherapy plus either intravenous durvalumab or a placebo (1:1 ratio) once every 3 weeks for four cycles. After undergoing surgery, they received the same treatment once every 4 weeks for 12 cycles.

With an additional 18 months of follow-up, event-free survival appeared to continue to favor durvalumab vs the placebo (median, not reached [NR] vs 30.0 months; hazard ratio [HR] = 0.69), including within the subgroups treated with cisplatin-based (NR vs 45.0 months; HR = 0.58) and carboplatin-based (NR vs 26.2 months; HR = 0.75) chemotherapy. Treatment with durvalumab showed a clinically meaningful disease-free survival benefit (NR vs NR; HR = 0.66) and a trend toward improved overall survival (NR vs 53.2 months; HR = 0.89). Based on exploratory analyses, the event-free survival benefit was more pronounced in the adjuvant setting and favored durvalumab regardless of pathologic complete response status; an improvement in lung cancer–specific survival was observed (NR vs NR; HR = 0.70).

During the overall period, the maximum grade 3 or 4 adverse event rates were found to be similar with durvalumab (43.6%) and the placebo (43.2%). The rates were 15.4% and 10.6%, respectively, during the adjuvant period.

Disclosure: For full disclosure information, visit wclc2024.iaslc.org.

2024 World Conference on Lung Cancer

---